Latest Financial Services News

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

Regal Asian Investments has commenced on-market share purchases to satisfy its Dividend Reinvestment Plan, pricing shares at or below its recent net tangible asset value of $2.54. This move signals a strategic approach to capital management amid evolving portfolio stewardship.

BlackRock is reshaping its iShares Future Tech Innovators ETF by narrowing its focus to the 30 largest Nasdaq 100 companies and cutting management fees nearly in half, effective October 15, 2025.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

Hearts and Minds Investments Limited (HM1) reported a stellar FY25 with total comprehensive income soaring to $124.8 million, nearly doubling the prior year, alongside a dividend increase and sustained philanthropic commitments.

Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.